Creatine kinase and platelet aggregation

Creatine kinase and platelet aggregation - Creatine kinase and platelet aggregation

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON34637

Enrollment

Registered

2010-12-30

Start date

2010-11-01

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

blood coagulation platelet aggregation

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: healthy men, 18-50 Y

Exclusion criteria

Exclusion criteria: personal and family history of bleeding or coagulation abnormalities, drug use, use of acetylsalicylic acid or other non-steroidal anti-inflammatory drugs in the past week, current smoking, BMI>/= 30 kg/m2; glucose, lipid spectrum, thyroid, kidney, or liver abnormalities, sickle cell disease.

Design outcomes

Primary

Measure	Time frame
Main study parameters/endpoints: Difference in ADP induced platelet aggregation with low vs high serum CK.	—

Secondary

Measure	Time frame
Differences in study groups between other blood parameters, including platelet count, aPTT, PT, fibrinogen, spontaneous platelet aggegation, P-selectin, collagen, arachidon acid and ristocetine aggregation tests (before and after 80 mg aspirin), clopidogrel resistance, ADP/ATP ratio in platelets, creatine, creatinine	—

Countries

Netherlands

Outcome results